Owlin adds Consumer Sentiment & Review Data to its offering in its journey to transform risk management for Payment Service Providers
12.9.2023 16:00:00 EEST | Business Wire | Press release
Owlin, a global leader in merchant and third-party risk solutions, proudly announces its next big step in advancing the fintech industry: a new Consumer Review Data feature, specifically designed for Risk teams within Payment Service Providers (PSPs). Operational excellence becomes more important than ever for PSPs and manual review processes are often costly, reactive and inefficient. Owlin's latest offering heralds a transformative shift towards proactive, cost-effective, and highly efficient risk management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230912980645/en/
Owlin for Consumer Review Monitoring for Payment Service Providers (PSPs) (Photo: Business Wire)
One of the standout features of Owlin's Consumer Review Feature is its unparalleled ability to detect leading risk signals, such as signs of distress (e.g., delivery- or product issues) well ahead of bigger issues like a bankruptcy event. This capability provides PSPs with a significant advantage in proactively mitigating risk, preventing potential financial disasters, and safeguarding their operations and reputation.
Furthermore, Owlin's Consumer Review Feature is a significant advantage in the world of adverse media monitoring, helping improve merchant risk management. It builds upon Owlin's already world-class monitoring solution for PSPs and it gives PSPs the tools they need to stay competitive.
Key Features and Benefits:
- Real-time Feedback and Risk Alerts - Instantly gather consumer feedback and correlate it with advanced risk signals, alerting PSPs to potential risks well in advance.
- Advanced Analytics - Utilize AI-driven insights powered by large language models to gauge sentiment, track trends, and pinpoint areas requiring risk mitigation.
- Enhanced Engagement and Trust Building - Responsively address concerns, showcase negative reviews, risk mitigating actions, and fortify trust in the PSP ecosystem.
- In-depth Risk Profiles - Craft comprehensive risk profiles based on a blend of signals and consumer feedback, ensuring that risk management decisions are data-driven and merchant-centric.
Stefan Peekel, Chief Growth Officer at Owlin, remarks, “By integrating consumer review data into risk management practices, we're giving PSPs a comprehensive tool that's been absent in the industry. It's not just about enhancing services but also about fortifying them against threats. In essence we now equip PSPs with a magnifying glass and a map. While they get a detailed view of consumer sentiment on a merchant, they also see how signals interconnect, allowing them to preempt risks and capitalize on opportunities.’’
Dedicated to innovation, Owlin keeps pushing to redefine what is possible in the domain of risk management. With this latest consumer review offering Payment Service Providers are equipped with a new set of state of the art tools to manage risk effectively and build trust for merchants and consumers.
About Owlin
Owlin is an AI-driven Third Party Risk and Merchant Monitoring solution that helps businesses feed better and faster risk insights into daily risk management workflows in real time. Owlin applies AI and Natural Language Processing to provide valuable insights hidden in the data and ensures its users don’t get lost in the wealth of information by visualizing complex data in a simple and customizable interface.
For more information, visit https://owlin.com/solutions/consumer-review-monitoring/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912980645/en/
Contact information
Contact Owlin: Stefan Peekel, stefan@owlin.com, +1 201 932 4580
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
